Eliem Therapeutics Inc (ELYM) Financial Statements (2025 and earlier)

Company Profile

Business Address 20 WILLIAM STREET
WELLESLEY HILLS, MA 02481
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:106,798123,600161,400
Cash and cash equivalents93,11243,58546,922
Short-term investments13,68679,98189,558
Other undisclosed cash, cash equivalents, and short-term investments  3424,920
Prepaid expense8471,3301,491
Other undisclosed current assets2,6109,463(14,639)
Total current assets:110,255134,393148,252
Noncurrent Assets
Operating lease, right-of-use asset199471 
Long-term investments and receivables  24,919
Long-term investments  24,919
Other noncurrent assets 1512870
Total noncurrent assets:21459924,989
TOTAL ASSETS:110,469134,992173,241
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,4995,7975,992
Accounts payable667501,404
Accrued liabilities2,4335,0474,588
Other liabilities   
Other undisclosed current liabilities33430039
Total current liabilities:2,8336,0976,031
Noncurrent Liabilities
Liabilities, other than long-term debt 371807
Other liabilities 22 7
Operating lease, liability 15180 
Total noncurrent liabilities: 371807
Total liabilities:2,8706,2776,038
Equity
Equity, attributable to parent107,599128,715167,203
Common stock333
Additional paid in capital263,577249,930242,939
Accumulated other comprehensive income (loss)(2)(358)(123)
Accumulated deficit(155,979)(120,860)(75,616)
Total equity:107,599128,715167,203
TOTAL LIABILITIES AND EQUITY:110,469134,992173,241

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues   
Other operating income   
Gross profit:   
Operating expenses(40,275)(45,135)(35,672)
Other undisclosed operating loss   
Operating loss:(40,275)(45,135)(35,672)
Nonoperating income (expense)5,460(517)(12,053)
Gain (loss), foreign currency transaction, before tax304(408)(245)
Other nonoperating income (expense)5,156(109)(11,808)
Loss from continuing operations:(34,815)(45,652)(47,725)
Loss before gain (loss) on sale of properties:(47,725)
Other undisclosed net income (loss)(304)408245
Net loss attributable to parent:(35,119)(45,244)(47,480)
Other undisclosed net loss available to common stockholders, basic   (4,548)
Net loss available to common stockholders, diluted:(35,119)(45,244)(52,028)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(35,119)(45,244)(47,480)
Other comprehensive income (loss)356(235)(123)
Other undisclosed comprehensive income   
Comprehensive loss:(34,763)(45,479)(47,603)
Comprehensive income, net of tax, attributable to noncontrolling interest   47,603
Other undisclosed comprehensive loss, net of tax, attributable to parent   
Comprehensive loss, net of tax, attributable to parent:(34,763)(45,479) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: